Abstract
Sendai virus vector is emerging as a promising vector for gene therapy, and angiopoietin-1 (Ang-1) has been reported to improve the blood flow recovery in the ischemic limb or heart. In this study, we constructed a human Ang-1-expressing Sendai viral vector (SeVhAng-1) and injected it into the ischemic limb of rats. We found that SeVhAng-1 improved the blood flow recovery and increased the capillary density of the ischemic limb, compared with the controls. We also found that SeVhAng-1 increased p-Akt during the early period of limb ischemia, and decreased apoptosis in ischemic limb. It suggests that SeVhAng-1 may serve as a potential therapeutic tool in ischemic limb disease.
Publication types
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiopoietin-1 / administration & dosage*
-
Angiopoietin-1 / genetics
-
Animals
-
Constriction, Pathologic / genetics
-
Constriction, Pathologic / pathology
-
Constriction, Pathologic / therapy
-
Disease Models, Animal
-
Gene Transfer Techniques
-
Genetic Therapy
-
Genetic Vectors* / administration & dosage
-
Genetic Vectors* / genetics
-
Genetic Vectors* / physiology
-
Humans
-
Iliac Artery / pathology
-
Injections, Intramuscular
-
Ischemia / genetics
-
Ischemia / pathology
-
Ischemia / therapy*
-
Lower Extremity / blood supply*
-
Lower Extremity / pathology
-
Male
-
Peripheral Vascular Diseases / genetics
-
Peripheral Vascular Diseases / pathology
-
Peripheral Vascular Diseases / therapy*
-
Rats
-
Rats, Inbred Lew
-
Sendai virus / genetics*
-
Sendai virus / physiology